Palantir Technologies lifts guidance after Q2 results beat Wall Street estimates
TURKU, Finland - Faron Pharmaceuticals Ltd (AIM:FARN, First North: FARON), a biopharmaceutical company focused on developing immunotherapies, has registered 5,352,989 new shares today, as part of a previously announced rights issue and treasury share allocation. The registration follows the approval of 352,989 new shares subscribed using special rights, amounting to a subscription price of EUR 907,499.42.
Last week, on May 27, 2025, the company’s Board of Directors resolved to issue 5,000,000 treasury shares to the company itself at no cost, in preparation for potential future conversions of its First Tranche Bond. The newly registered shares are expected to start trading on the First North and AIM markets around June 4, 2025.
With this addition, Faron’s total issued share capital now stands at 116,954,597 shares, which includes the 5,000,000 shares held in treasury. These treasury shares do not confer any shareholder rights, such as voting or dividend entitlements. As a result, the total number of voting rights in the company is now 111,954,597.
This registration of new shares could be significant for investors as it alters the total number of shares and voting rights available, which is a key figure for shareholders to determine any changes in their percentage holdings.
The information provided in this article is based on a press release statement from Faron Pharmaceuticals Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.